Evidence map›Paper›PMID 35892374›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Halogenated Pyrrolopyrimidines with Low MIC on

Cecilie Elisabeth Olsen, Fredrik Heen Blindheim, Caroline Krogh Søgaard, Lisa Marie Røst, Amanda Holstad Singleton, Olaug Elisabeth Torheim Bergum, Per Bruheim, Marit Otterlei, Eirik Sundby, Bård Helge Hoff

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Antibiofilm Activities of Multiple Halogenated Pyrimidines AgainstInternational journal of molecular sciences · 2024
    Article
  3. Activation of multiple stress responses inFrontiers in microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Cecilie Elisabeth OlsenDepartment of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Fredrik Heen BlindheimDepartment of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Caroline Krogh SøgaardDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), NO-7489 Trondheim, Norway.
Lisa Marie RøstDepartment of Biotechnology and Food Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.ORCID 0000-0003-3980-8667
Amanda Holstad SingletonDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), NO-7489 Trondheim, Norway.
Olaug Elisabeth Torheim BergumDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), NO-7489 Trondheim, Norway.
Per BruheimDepartment of Biotechnology and Food Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.ORCID 0000-0002-7851-8083
Marit OtterleiDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), NO-7489 Trondheim, Norway.ORCID 0000-0002-5232-1186
Eirik SundbyDepartment of Material Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Bård Helge HoffDepartment of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.ORCID 0000-0001-7859-7810
Norwegian University of Science and Technology · NO

Funding

Norwegian University of Science and Technology (NTNU) No grant numberTrond Mohn Fundation No grant number
6 · The paper itself

Abstract

Currently, there is a world-wide rise in antibiotic resistance causing burdens to individuals and public healthcare systems. At the same time drug development is lagging behind. Therefore, finding new ways of treating bacterial infections either by identifying new agents or combinations of drugs is of utmost importance. Additionally, if combination therapy is based on agents with different modes of action, resistance is less likely to develop. The synthesis of 21 fused pyrimidines and a structure-activity relationship study identified two 6-aryl-7

Indexed as

antibacterialhalogenated antibioticpyrrolopyrimidinessynergistic effect

Identifiers

PMID35892374
PMCPMC9330635
OpenAlexW4286587402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.